109 related articles for article (PubMed ID: 10495435)
1. Involvement of the c-erbB-2 oncogene product in the EGF-induced cell motility of SK-OV-3 ovarian cancer cells.
Wiechen K; Karaaslan S; Dietel M
Int J Cancer; 1999 Oct; 83(3):409-14. PubMed ID: 10495435
[TBL] [Abstract][Full Text] [Related]
2. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.
Wiechen K; Karaaslan S; Turzynski A; Dietel M
Br J Cancer; 1999 Nov; 81(5):790-5. PubMed ID: 10555747
[TBL] [Abstract][Full Text] [Related]
3. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation.
Hsieh SS; Malerczyk C; Aigner A; Czubayko F
Int J Cancer; 2000 Jun; 86(5):644-51. PubMed ID: 10797285
[TBL] [Abstract][Full Text] [Related]
4. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value.
Meden H; Marx D; Raab T; Kron M; Schauer A; Kuhn W
J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):167-78. PubMed ID: 8556578
[TBL] [Abstract][Full Text] [Related]
5. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
Hwang MS; Yum YN; Joo JH; Kim S; Lee KK; Gee SW; Kang HI; Kim OH
Anticancer Res; 2001; 21(4A):2649-55. PubMed ID: 11724334
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met.
Corps AN; Sowter HM; Smith SK
Int J Cancer; 1997 Sep; 73(1):151-5. PubMed ID: 9334823
[TBL] [Abstract][Full Text] [Related]
8. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells.
Marth C; Lang T; Cronauer MV; Doppler W; Zeimet AG; Bachmair F; Ullrich A; Daxenbichler G
Int J Cancer; 1992 Sep; 52(2):311-6. PubMed ID: 1355758
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase.
Zhou HY; Pon YL; Wong AS
Endocrinology; 2007 Nov; 148(11):5195-208. PubMed ID: 17673518
[TBL] [Abstract][Full Text] [Related]
11. Stable suppression of HER-2 gene expression using siRNA increases the lysis of human ovarian carcinoma cells mediated by NK-92 cell line.
Zhou Y; Cheng Z; Zhu H; Feng D; Zhao W; Ling B; Wei H; Tian Z
Oncol Rep; 2008 Dec; 20(6):1425-31. PubMed ID: 19020724
[TBL] [Abstract][Full Text] [Related]
12. Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma.
Ito K; Sasano H; Ozawa N; Sato S; Silverberg SG; Yajima A
Int J Gynecol Pathol; 1992 Oct; 11(4):253-7. PubMed ID: 1356938
[TBL] [Abstract][Full Text] [Related]
13. The overexpressed regucalcin represses the growth via regulating diverse pathways linked to EGF signaling in human ovarian cancer SK-OV-3 cells: Involvement of extracellular regucalcin.
Yamaguchi M; Murata T; Ramos JW
Life Sci; 2023 Feb; 314():121328. PubMed ID: 36584916
[TBL] [Abstract][Full Text] [Related]
14. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.
Meden H; Kuhn W
Eur J Obstet Gynecol Reprod Biol; 1997 Feb; 71(2):173-9. PubMed ID: 9138962
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
17. METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells.
Wu GJ; Zeng GF
BMC Cancer; 2016 Feb; 16():136. PubMed ID: 26906545
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy.
Meden H; Marx D; Fattahi A; Rath W; Kron M; Wuttke W; Schauer A; Kuhn W
J Cancer Res Clin Oncol; 1994; 120(6):378-81. PubMed ID: 7908021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
